Innoviva, Inc. (INVA) — closed signal from March 12, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 10, 2026.
Predicted vs. what happened
What happened
Reached 51% of the predicted growth at its peak, without hitting the target.
The thesis — published March 12, 2026
INVA is a steadier biotech idea because it earns money from both royalties and its own drugs. A higher analyst target and the valuation case suggest upside, but trading is thin so moves can be slow. Be patient: if buyers keep the stock in the low-$20s, the next quarterly results could help the stock move higher.
Primary drivers
- Royalties plus owned drugs give more stable income
- Higher analyst target adds interest from buyers
- Recent pullback makes buying levels more favorable
- Less likely to swing wildly like single-drug biotechs
How it played out
INVA: target was not reached by June 10
Lyra published INVA on March 12 at $22.19 as a short-term thesis with expected growth of 20%. The thesis pointed to royalties plus owned drugs, a higher analyst target, a recent pullback, and a view that the stock was less likely to swing like single-drug biotechs. The target was $26.63.
Inside the window, INVA rose to a peak of $24.45 on April 20, a 10.2% gain. It never reached the target. By June 10, the stock ended at $23. The thesis partially played out because the stock rose, but the move stayed below the published target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.